Questions & explanations
1. How do TB control programs in India differ from those in high-income countries like the United States?
In India, the TB control program is run by the government under the Revised National Tuberculosis Control Program (RNTCP), now called the National TB Elimination Program (NTEP). It provides free diagnosis and treatment using DOTS, with a focus on finding cases in the community. In the United States, TB control is managed by local health departments, and treatment is often given by private doctors. The US has fewer cases and focuses on screening high-risk groups like immigrants and homeless people. India has a much larger burden, so its program uses widespread public health measures, including mobile vans for X-rays and community health workers. Both aim to cure patients and prevent spread, but India faces more challenges due to poverty and population density.
2. Compare the health impact of outdoor air pollution in a city like Delhi versus a rural area in India.
In Delhi, outdoor air pollution is very high due to vehicle traffic, industry, and crop burning. People breathe in high levels of PM2.5 year-round, leading to high rates of asthma, COPD, and lung cancer. In rural areas, outdoor pollution is lower, but indoor pollution from cooking fires is a major problem. Rural women and children suffer from lung diseases due to indoor smoke. Both settings have serious health impacts, but the sources differ. Delhi's pollution affects everyone outdoors, while rural pollution mainly affects those near the stove. Both need different solutions: reducing vehicle emissions in cities and providing clean cooking stoves in villages.
3. Compare the treatment of a child with pneumonia in a high-resource setting versus a low-resource setting.
In a high-resource setting, a child with pneumonia is usually taken to a hospital, gets a chest X-ray and blood tests, and receives intravenous antibiotics (through a vein) and oxygen. Doctors monitor them closely, and they often recover quickly. In a low-resource setting, the child may be seen by a community health worker who counts breaths and gives oral antibiotics. If the case is severe, the child might be referred to a clinic, but transport and money are problems. Oxygen may not be available. Many children in low-resource settings die from pneumonia that would be easily treated in a rich country. The key difference is access to timely, quality care.
4. How do Type I and Type III interferons differ in their role against respiratory viruses?
Type I IFNs (IFN-α/β) act on many cell types, including immune cells, and induce strong antiviral and inflammatory responses. Type III IFNs (IFN-λ) mainly act on epithelial cells, like those lining the respiratory tract. Type III IFNs provide antiviral protection at mucosal surfaces with less inflammation, reducing tissue damage. Both are induced by viral infection, but Type III is often produced earlier and in larger amounts in the lung. For example, in influenza, Type III IFNs are crucial for controlling virus in the airway epithelium. Type I IFNs are more systemic and can cause fever and malaise. The balance between them determines disease outcome.
5. Compare the roles of surface TLRs (TLR2, TLR4) versus endosomal TLRs (TLR3, TLR7) in respiratory defense.
Surface TLRs (TLR2, TLR4) detect bacterial components outside the cell, like peptidoglycan and LPS. They trigger rapid inflammatory responses and phagocytosis. Endosomal TLRs (TLR3, TLR7, TLR8, TLR9) detect nucleic acids from viruses that have been taken up into endosomes. They induce interferons, which are key for antiviral defense. Surface TLRs are more involved in bacterial clearance, while endosomal TLRs specialize in viral recognition. Both types work together: for example, during a mixed infection, surface TLRs handle bacteria and endosomal TLRs handle viruses. Dysregulation of either can lead to chronic inflammation or autoimmunity.
6. Compare the impact of outdoor air pollution versus indoor air pollution on respiratory health globally.
Both outdoor and indoor air pollution cause serious lung diseases. Outdoor air pollution comes from vehicles, factories, and power plants, and it increases the risk of asthma, COPD, and lung cancer. It affects people in cities worldwide, especially in developing countries. Indoor air pollution comes from burning solid fuels like wood, coal, or dung for cooking and heating. It mainly affects women and children in poor rural homes who spend many hours near the fire. Indoor pollution causes pneumonia in children and COPD in women. Globally, indoor air pollution causes more deaths than outdoor pollution, but both are major health problems.
7. Compare the antiviral state induced by interferons with the effect of a vaccine.
Interferons create a temporary, non-specific antiviral state in cells that lasts days. They inhibit a broad range of viruses by blocking replication and enhancing immune recognition. A vaccine, on the other hand, induces long-lasting, specific immunity through memory B and T cells. Vaccines target a particular pathogen, while interferons act against many viruses at once. However, interferons do not provide memory; their effect wanes quickly. Vaccines require weeks to develop protection but can last years. In acute infection, interferons are the first line of defense; vaccines prevent infection by prearming the adaptive immune system.
8. Why might low levels of surfactant proteins increase risk of respiratory infections?
Low SP-A and SP-D levels weaken the lungs' first line of defense. Without enough opsonins, pathogens can evade immune detection and multiply. This is seen in premature infants who lack surfactant, making them prone to respiratory distress and infections. In adults, genetic variations or smoking can reduce surfactant protein levels. Animal studies show that mice lacking SP-A or SP-D are more susceptible to influenza and bacterial pneumonia. Supplementing surfactant proteins in therapy is being explored, but challenges include delivery and avoiding immune overactivation. Thus, maintaining adequate levels is important for lung health.
9. What are interferons and how do they protect against respiratory viruses?
Interferons (IFNs) are signaling proteins released by infected cells to warn neighboring cells. There are three types: Type I (IFN-α/β), Type II (IFN-γ), and Type III (IFN-λ). When a cell detects a virus, it produces IFNs that bind to receptors on nearby cells. This triggers hundreds of genes that create an 'antiviral state', making cells resistant to infection. IFNs also activate immune cells like natural killer cells and macrophages. In the lungs, Type III IFNs are especially important because they act on epithelial cells without causing widespread inflammation. Without IFNs, viruses like influenza would spread uncontrollably.
10. How do SP-A and SP-D tell apart harmful pathogens from harmless particles?
SP-A and SP-D recognize patterns on pathogen surfaces, such as lipopolysaccharide on Gram-negative bacteria or mannose-rich glycoproteins on viruses. These patterns are not present on host cells or harmless dust. The proteins have carbohydrate recognition domains that bind specifically to these microbial sugars. They also detect lipid components like lipoteichoic acid on Gram-positive bacteria. This selective binding triggers immune responses only against threats. Additionally, they can aggregate pathogens, preventing them from spreading. The ability to distinguish self from non-self is key to avoiding unnecessary inflammation.
11. What is large cell carcinoma?
Large cell carcinoma is a type of lung cancer where the cells look big and round under a microscope. It is a non-small cell lung cancer (NSCLC) that does not have clear features of other types like adenocarcinoma or squamous cell carcinoma. Some large cell carcinomas have neuroendocrine features, meaning they act like hormone-producing cells. Immunohistochemistry uses special stains to find these neuroendocrine markers, such as chromogranin or synaptophysin. This helps doctors tell it apart from other lung cancers. Large cell neuroendocrine carcinoma (LCNEC) is a more aggressive subtype that behaves like small cell lung cancer.
12. What are health disparities in asthma?
Health disparities in asthma are differences in how often asthma occurs and how well it is controlled among different groups of people. For example, Black and Hispanic children in the United States have higher rates of asthma and more emergency visits than white children. People with low income often live in areas with more pollution and poor housing, which worsen asthma. They may also have less access to doctors and medicines. These differences are not due to biology alone but are caused by social and economic factors. Addressing disparities means making sure everyone gets good care and lives in a healthy environment.